Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 16 chart positions in 16 markets.
By chart position
- 🇺🇸US · Life Sciences#1505K to 30K
- 🇦🇺AU · Life Sciences#1975K to 30K
- 🇮🇳IN · Life Sciences#5410K to 30K
- 🇰🇷KR · Life Sciences#7210K to 30K
- 🇳🇱NL · Life Sciences#1181K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
23K to 103K🎙 Weekly cadence·55 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
46K to 205K🇺🇸15%🇦🇺15%🇮🇳15%+13 more - Active Followers
Loyal subscribers who consistently listen
14K to 62K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 11 epsHost
Recent guests
Recent episodes
Bioequivalence Testing: The Stats Behind Generic Drug Approvals (Ep. 57)
May 25, 2026
24m 13s
Examining Volume of Distribution (Ep. 56)
Apr 20, 2026
19m 22s
Talking about data science with Mike Stackhouse (Ep. 55)
Mar 16, 2026
45m 19s
Using Accelerator Mass Spectrometry in Clinical Pharmacology
Feb 16, 2026
38m 19s
Using AI tools for regulatory intelligence (Ep. 53)
Jan 19, 2026
21m 21s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 5/25/26 | Bioequivalence Testing: The Stats Behind Generic Drug Approvals (Ep. 57)✨ | bioequivalence testinggeneric drug approvals+3 | — | FDABioequivalence of generic drugs: a simple explanation for clinicians | — | bioequivalencegeneric drugs+3 | — | 24m 13s | |
| 4/20/26 | Examining Volume of Distribution (Ep. 56)✨ | Volume of Distributiondrug development+3 | — | Teuscher Solutions LLC | — | Volume of Distributiondrug development+3 | — | 19m 22s | |
| 3/16/26 | Talking about data science with Mike Stackhouse (Ep. 55)✨ | data scienceAI+3 | Michael Stackhouse | Atorus Research | — | data scienceAI+3 | — | 45m 19s | |
| 2/16/26 | Using Accelerator Mass Spectrometry in Clinical Pharmacology✨ | accelerator mass spectrometrydrug metabolism+3 | Dr. Wouter Vaes | Peregrion | — | accelerator mass spectrometrydrug metabolism+3 | — | 38m 19s | |
| 1/19/26 | Using AI tools for regulatory intelligence (Ep. 53)✨ | AI toolsregulatory intelligence+3 | Aruna Dhontabhaktuni | RegKeyTeuscher Solutions LLC | — | AIregulatory intelligence+3 | — | 21m 21s | |
| 12/22/25 | When to use model-informed drug development (Ep. 52)✨ | model-informed drug developmentdrug development schedule+3 | — | Teuscher Solutions LLC | — | model-informed drug developmentdrug development+3 | — | 28m 16s | |
| 11/24/25 | QSP Modeling with Ahmed Elmokadem (Ep. 51)✨ | QSP modelingclinical pharmacology+3 | Ahmed Elmokadem | Metrum Research GroupNumbers that Dazzled the World | — | QSP modelingclinical pharmacology+3 | — | 44m 37s | |
| 10/27/25 | CDISC datasets and ACoP 2025 (Ep. 50)✨ | CDISC datasetsdata standard+3 | — | CDISCTeuscher Solutions LLC | — | CDISCdataset-JSON+3 | — | 18m 46s | |
| 9/22/25 | Statistics in Pharmacokinetics (Ep. 49)✨ | pharmacokineticsstatistics+3 | — | Teuscher Solutions LLC | — | pharmacokineticsstatistics+4 | — | 25m 13s | |
| 8/25/25 | Clinical Trial Simulations (Ep. 48)✨ | clinical trial simulationsvariability terms+1 | — | Teuscher Solutions LLCTrial Simulator Software+1 | — | clinical trialsimulation+3 | — | 21m 30s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 7/28/25 | Using R Shiny for Clinical Pharmacology (Ep. 47)✨ | R Shinyclinical pharmacology+4 | — | Shinyapps.io | — | R Shinyclinical pharmacology+5 | — | 19m 37s | |
| 6/23/25 | What is useful about noncompartmental analysis? (Ep. 46) | In this episode I discuss noncompartmental analysis. I categorize PK parameters calculated by NCA methods as either Important, Useful, or Questionable. I also share my thoughts on how to report PK parameters calculated using NCA methods in nonclinical and clinical reports. I want to hear your thoughts about this episode. Do you agree or disagree with my categorization of PK parameters? Why? Use the links below to let me know.Links discussed in the show:You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLCAll Rights Reserved | — | ||||||
| 5/27/25 | How to select a base PK model (Ep. 45) | In this episode I review the process I follow for fitting a base pharmacokinetic (PK) model. I talk from the perspective of an individual PK model, but include some differences associated with population PK models. I go over exploratory data analysis, getting initial estimates, and how to choose between different base models.Links discussed in the show:AIC and BICYou can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLCAll Rights Reserved | — | ||||||
| 4/21/25 | Different estimation methods used in modeling (Ep. 44) | In this episode I discuss different algorithms used for pharmacometrics modeling. I describe difference between maximum likelihood and expectation maximization methods. I review the FO and FOCEI maximum likelihood algorithms. I then review SAEM, IMP, and QRPEM expectation maximization algorithms that are available. I conclude with an brief explanation of the difference between parameter estimation and parameter uncertainty. Links discussed in the show:PMXRepoJames Ousey LinkedIn pageManuscript by Liu and Wang, 2016You can connect with me on LinkedIn and send me a messageSend me a messageSign up for my newsletterCopyright Teuscher Solutions LLCAll Rights Reserved | — | ||||||
| 3/24/25 | What is consulting life like? (Ep. 43) | In this episode I discuss my experience as an independent consultant in the clinical pharmacology and pharmacometrics space. I talk about how I got from high school to become a consultant. I touched on the many different activities I do as an independent consultant. I shared a bit about how I handle compensation with clients and how I pay myself. And I ended with some brief comments about getting customers. Links discussed in the show:Time management with Clockify Accounting and invoices with Wave Project management with Jira Project notes with Confluence Computing resources with AWS Microsoft 365 for email, sharepoint, and more as a small business Profit First You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLCAll Rights Reserved | — | ||||||
| 2/24/25 | Population PK modeling with nlmixr (Ep. 42) | In this episode I discuss using nlmixr for population PK modeling in R. I give an overview of the software package, describe the installation process, and walk through a simple example. Overall, nlmixr is a nice package that can be used for most modeling activities you encounter. It eliminates the need for a license since it is open-source. There are some challenges associated with using R for modeling with large datasets and long-running models. But once those are overcome, this could be a great package for all-around use. Links discussed in the show: nlmixr website nlmixr on github Example R code – remove the .txt file type after download You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletterCopyright Teuscher Solutions LLCAll Rights Reserved | — | ||||||
| 1/31/25 | Sample size calculations (Ep. 41) | In this episode I discuss power calculations using the R package PowerTOST. I gave an introduction to power calculations and the statistical premise. I reviewed bioequivalence study designs that are commonly used for generic drug development, food effect evaluation, and drug-drug interaction studies. Links discussed in the show: PowerTOST R package PowerTOST instructions (scroll down to the Read Me information) Example R code (Change the filetype to .R after downloading) Statistical Power Statistical approaches to establishing Bioequivalence from FDA Calculation of CV You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLC All Rights Reserved | — | ||||||
| 12/30/24 | Collaboration with BioTalk Unzipped (Ep. 40) | In this episode I share a couple short clips from my conversation with Chad Briscoe and Greg Austin from BioTalk Unzipped (www.biotalkunzipped.com). We chat about a variety of topics including artificial intelligence and challenges with cell therapy development. You can hear the entire conversation on the BioTalk Unizipped podcast or YouTube channel in January. For now, enjoy these clips from the upcoming show! Links discussed in the show: BioTalk Unzipped main page BioTalk Unzipped YouTube channel You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter | — | ||||||
| 12/9/24 | Toxicokinetics (Ep. 39) | In this episode I discuss toxicokinetic analysis. This is the analysis of exposure data to support animal toxicology studies. I review the purpose of toxicology studies and how exposure metrics are used. Then I discuss different blood sampling schemes, and how to calculate exposure parameters for both full profiles and mean profiles. Links discussed in the show: You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLC All Rights Reserved | — | ||||||
| 11/25/24 | Steady State (Ep. 38) | This episode is a discussion of steady state pharmacokinetics. Steady state occurs when the amount of drug input is equivalent to the amount of drug elimination in a dosing interval. I discuss some key PK parameters at steady state and how to use them. I also discuss different methods of confirming that you have reached steady state. Links discussed in the show: You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLC All Rights Reserved | — | ||||||
| 11/11/24 | Dose Proportionality (Ep. 37) | In this episode I talk about dose proportionality, which is a surrogate for determining if we have linear clearance across a range of dose levels. I discuss 3 different methods that people use to determine dose proportionality along with a recommendation to use the power model method. Links discussed in the show: Power model method You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter | — | ||||||
| 10/28/24 | Covariate Search Methods (Ep. 36) | This episode is a discussion of covariate search methods. I give definitions of covariates and predictors, and then I describe 3 different covariate search methods. For each method I describe the pros and cons associated with each one, including bias and time limitations. Links discussed in the show: Evaluation of the Boruta method for covariate selection You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLC All Rights Reserved | — | ||||||
| 10/14/24 | Stimulatory Indirect Response PK-PD Models (Ep. 35) | In this episode I describe stimulatory indirect response PK-PD models. I describe how they work, how to set up the dataset for NONMEM, and how to code the model in NONMEM. This is the last of 4 episodes on different PK-PD models. Links discussed in the show: Indirect response PK-PD model equations Example NONMEM code for stimulatory indirect response PK-PD model You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLC All Rights Reserved | — | ||||||
| 9/23/24 | Inhibitory Indirect Response PK-PD Models (Ep. 34) | In this episode I describe inhibitory indirect response PK-PD models. I describe how they work, how to set up the dataset for NONMEM, and how to code the model in NONMEM. This is the third of 4 episodes on different PK-PD models. Links discussed in the show: Indirect response PK-PD model equations Example NONMEM code for inhibitory indirect response PK-PD model You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLC All Rights Reserved | — | ||||||
| 9/9/24 | Effect compartment PK-PD models (Ep. 33) | In this episode I describe effect compartment PK-PD models. I describe how they work, a method of creating exploratory plots, how to set up the dataset for NONMEM, and how to code the model in NONMEM. This is the 2nd of 4 episodes on different PK-PD models. Links discussed in the show: Example NONMEM code for effect compartment model You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLC All Rights Reserved | — | ||||||
Showing 25 of 57
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
16 placements across 16 markets.
Chart Positions
16 placements across 16 markets.